Stock Events

Stock Events

Soligenix 

0
91
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6NovExpected
Q1 2026
Q2 2026
Next
-0.24
-0.19
-0.14
-0.09
Expected EPS
-0.09038399999999999
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-9.67MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DOA2.MU. It's not an investment recommendation.
NVIDIA
15
NVDA
Microsoft
13
MSFT
Tesla
13
TSLA
Palantir Technologies
12
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation operates in the same biopharmaceutical sector focusing on innovative therapies, directly competing in areas of immunology and oncology similar to Soligenix's pipeline.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that develops and markets drugs in areas overlapping with Soligenix's focus, including treatments for infectious diseases, potentially competing in the development of treatments for conditions like COVID-19.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. competes in the biotech space, focusing on innovative human therapeutics. Their work in immune-oncology and inflammatory diseases competes with Soligenix's research and product development.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biopharmaceuticals, directly competing with Soligenix in the development of treatments for rare diseases and conditions requiring novel therapeutic approaches.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals Incorporated operates in the biotechnology industry, focusing on creating new possibilities in medicine. Their work on cystic fibrosis and other serious diseases competes with Soligenix's efforts in rare diseases.
Biogen
BIIB
Mkt Cap32.28B
Biogen Inc. focuses on neurology, autoimmune and rare diseases, areas that overlap with Soligenix's therapeutic development, making them a competitor in the biopharmaceutical market.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk A/S is a global healthcare company with a strong focus on diabetes care and other serious chronic conditions, potentially competing with Soligenix in the broader healthcare market.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. is a global biopharmaceutical company with a wide range of products in various therapeutic areas, including those that compete with Soligenix's focus areas.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. operates globally in pharmaceuticals, offering products that directly compete with Soligenix's in areas like oncology and infectious diseases.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson is a broad healthcare company that, through its pharmaceutical division, competes with Soligenix in developing treatments for a wide range of diseases, including areas of focus for Soligenix.

About

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Show more...
CEO
Christopher J. Schaber
Employees
14
Country
United States
ISIN
US8342233074
WKN
000A3D506

Listings

LSE
GB
0A6I.LSE
MU
DE
DOA2.MU
MU
DE
DOA0.MU
XNAS
US
SNGX

0 Comments

Share your thoughts

FAQ

What is Soligenix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Soligenix stocks are traded under the ticker DOA2.MU.
When is the next Soligenix earnings date?▼
Soligenix is going to release the next earnings report on November 06, 2026.
What were Soligenix earnings last quarter?▼
DOA2.MU earnings for the last quarter are -0.1 EUR per share, whereas the estimation was -0.13 EUR resulting in a +22.58% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Soligenix revenue for the last year?▼
Soligenix revenue for the last year amounts to 0 EUR.
What is Soligenix net income for the last year?▼
DOA2.MU net income for the last year is -9.67M EUR.
How many employees does Soligenix have?▼
As of September 05, 2026, the company has 14 employees.
In which sector is Soligenix located?▼
Soligenix operates in the Health & Wellness sector.
When did Soligenix complete a stock split?▼
The last stock split for Soligenix was on February 10, 2023 with a ratio of 1:15.
Where is Soligenix headquartered?▼
Soligenix is headquartered in PRINCETON, United States.